| Status | In progress |
| Technology type | Medicine |
| Decision | Awaiting decision |
| Process | STA Standard |
| ID number | 6339 |
Provisional Schedule
| Committee meeting | 10 April 2025 |
| Expected publication | 02 July 2025 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors | Bristol Myers-Squibb (adagrasib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| Association of Respiratory Nurse Specialists | |
| British Thoracic Oncology Group | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services | |
| Relevant research groups | Institute of Cancer Research |
| National Institute for Health & Care Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 September 2024 | Invitation to participate |
| 09 July 2024 - 06 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6339 |
| 09 July 2024 | In progress. Scoping commenced. |
| 19 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 26 June 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual